Rare diseases are only rare if you don’t live with one.™
Quoin Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development of therapeutic products for rare and orphan diseases.
We are dedicated to supporting underserved patients and their families, communities, and care teams around the world.
|NASDAQ CM: QNRX||$2.14|
|52 Week High||$28.11|
|52 Week Low||$1.11|
Feb 9, 2023 10:33 AM EST
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome
Company’s Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing. All Six Target Clinical Sites are on Track to be Fully Opened by Year End.
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results
Company completed a public offering for aggregate gross proceeds of $16.8 million. Majority of clinical sites now open in clinical study to evaluate QRX003 for Netherton Syndrome.
Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th
Company announced today updated timing for its third quarter 2022 business update conference call and webcast.
Quoin Pharmaceuticals Ltd., Third Quarter Financial Results and Business Update Conference Call
Second Quarter Financial Results and Business Update Conference Call
Maxim 2022 Virtual Growth Conference